

1 **Title**

2 Diagnostic accuracy of point-of-care testing (POCT) devices for postpartum haemorrhage: A
3 protocol of a systematic review and meta-analysis

4
5 **Author names and affiliations**

6 Eishin Nakamura^{1,2}, Takahiro Mihara¹, Yuriko Kondo¹, Hisashi Noma³, Sayuri Shimizu¹

7 ¹Department of Health Data Science, Yokohama City University Graduate School of Data Science,
8 Yokohama, Japan

9 ²Center for Maternal, Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical
10 University, Saitama, Japan

11 ³The Institute of Statistical Mathematics, Tokyo, Japan

12

13 **Author list**

14 1. Eishin Nakamura

15 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
16 Yokohama, Japan

17 Center for Maternal, Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical
18 University, Saitama, Japan

19 2. Takahiro Mihara

20 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
21 Yokohama, Japan

22 3. Yuriko Kondo

23 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
24 Yokohama, Japan

25 4. Hisashi Noma

26 The Institute of Statistical Mathematics, Tokyo, Japan

27 5. Sayuri Shimizu

28 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
29 Yokohama, Japan

30

31 **Corresponding author**

32 Takahiro Mihara

33 Department of Health Data Science, Yokohama City University Graduate School of Data Science,
34 Yokohama City University

35 22-2 Seto, Kanazawa-ku, Yokohama, Kanagawa

36 Tel: 81-45-787-2311

37 E-mail: meta.analysis.r@gmail.com

38 **Keywords:** postpartum haemorrhage, point-of-care testing devices, hypofibrinogenaemia

39

40

41 **ABSTRACT**

42 **Introduction**

43 In postpartum haemorrhage (PPH), coagulation factors, mainly fibrinogen, are exhausted early
44 during the course of the disease, which can easily lead to disseminated intravascular coagulation
45 (DIC) and cause maternal mortality. Although some studies have reported the efficacy of
46 point-of-care testing (POCT) devices in detecting hypofibrinogenaemia, little research has been
47 conducted on their usefulness in the diagnosis of PPH. We plan to perform a systematic review of
48 the diagnostic accuracy of existing POCT devices for the diagnosis of hypofibrinogenaemia in PPH.

49 **Methods and analysis**

50 We plan to identify studies using POCT devices for PPH and perform a systematic review and
51 meta-analysis of their accuracy of diagnosing hypofibrinogenaemia. The results of fibrinogen
52 measurements using the conventional Clauss method are used as reference standards. Literature
53 searches will be conducted using electronic databases (MEDLINE, Embase, Cochrane Database, and
54 Web of Science), and two reviewers will screen independently from the search results. The eligible
55 literature will be used to synthesise true positive, false positive, true negative, and false negative
56 results for the diagnosis of hypofibrinogenaemia. We will estimate the diagnostic accuracy of POCT
57 devices for diagnosing hypofibrinogenaemia in patients with PPH using the Reitsma-type bivariate
58 random-effects synthesis model and the hierarchical summary receiver operating characteristic
59 curve.

60 **Ethics and dissemination**

61 This systematic review will be conducted through the secondary use of literature extracted from
62 electronic databases. There are no ethical issues associated with this research. The final integrated
63 results will be submitted to a peer-reviewed journal.

64 **Protocol registration**

65 The study protocol was registered with University Hospital Medical Information Network Clinical
66 Trials (UMIN000048272) and PROSPERO (CRD42023394785).

67 **Strengths and limitations of the study**

- 68
- 69 • Studies on the usefulness of POCT devices in the diagnosis of PPH are limited. Our study
70 will perform a systematic review of the diagnostic accuracy of existing POCT devices for
71 the diagnosis of hypofibrinogenaemia in PPH.
- 72
- 73 • The study will estimate the diagnostic accuracy of POCT devices using the Reitsma-type
74 bivariate random-effects synthesis model and the hierarchical summary receiver operating
75 characteristic curve.

- 76 • The threshold for diagnosing hypofibrinogenaemia, the definition of PPH, and the POCT
77 devices used may vary between studies and could be a potential source of heterogeneity.
78 Since most primary studies are observational, it is expected that many unpublished studies
79 will exist.
- 80
- 81 • The applicability of the study results may be limited since this systematic review only
82 pertains to the use of POCT devices in pregnant patients with PPH. The number of studies
83 may be limited since there is a wide variety of POCT devices used in PPH.
- 84
- 85
- 86
- 87

88 **INTRODUCTION**

89 **Background**

90 Postpartum haemorrhage (PPH) causes massive blood loss during labour and is one of the leading
91 causes of maternal death.(1) PPH often presents with severe coagulopathy complicated by
92 disseminated intravascular coagulation (DIC). The level of fibrinogen in the blood, which is
93 considered the first to fall below the haemostatic threshold is particularly important, and blood
94 fibrinogen levels correlate with the severity of PPH.(2) Early diagnosis of hypofibrinogenaemia and
95 the initiation of transfusion therapy are important for improving maternal outcomes.

96 Conventional fibrinogen testing using the Clauss method is time-consuming and expensive to be
97 installed in primary medical facilities. In recent years, point-of-care testing (POCT) devices that
98 simply estimate blood coagulation function have been used as an initial treatment for PPH, and there
99 are reports of their usefulness in PPH.(3) Moreover, the POCT device allows for rapid testing at a
100 low cost, and the test results correlate well with fibrinogen levels in conventional blood tests.(4)
101 Although many reports on the effectiveness of POCT devices in clinical practice have been
102 recognised in the fields of cardiovascular surgery(5) and emergency medicine(6), there are limited
103 reports on their use in PPH. Since PPH has a different mechanism than other haemorrhagic diseases
104 such as trauma or cardiac surgery, the usefulness of POCT in other diseases may not be directly
105 applicable.

106 Early diagnosis of coagulopathy, especially hypofibrinogenaemia, in patients with PPH, and
107 appropriate transfusion therapy may contribute to decreased total blood loss and mortality. Hence,
108 early diagnosis of coagulopathy using POCT devices is important for improving the prognosis of
109 PPH.

110

111 **Clinical role of the index test**

112 In clinical practice, dry haematology, thromboelastography, and thromboelastometry are commonly
113 used POCT devices.

114 Dry haematology can directly and rapidly measure fibrinogen by measuring the viscosity of the
115 magnetic particle motion signal using scattered light and calculating the fibrinogen value from the
116 absorbance.(7) Therefore, it is reasonable to use it for the diagnosis of PPH, in which fibrinogen
117 levels are particularly important, among other coagulation factors.

118 Thromboelastography enables the comprehensive evaluation of coagulation and haemostatic
119 function, including the effect of platelets, using whole blood samples. For TEG6s®, the parameters
120 that could be measured as actual values are 1. reaction time (R), 2. Kinetics (K), 3. Angle, 4.
121 maximum amplitude (MA), 5. whole blood clot lysis index at 30 minutes after MA(Ly30), 6.
122 amplitude 10(A-10) and 7. Functional fibrinogen (FLEV), 8. Activated clotting time (ACT) (8).
123 TEG6s can simultaneously measure four different reagents: Citrated Kaolin (CK), Citrated Kaolin

124 with Heparinase (CKH), Citrated Rapid TEG (CRT), Citrated Functional Fibrinogen (CFF), and
125 Citrated Rapid TEG (CRT).

126 The measurement principle of thromboelastometry is similar to that of thromboelastography but
127 requires a large number of reagents and pipetting steps. (9) Thromboelastography and
128 thromboelastometry often investigate and report parameters that correlate more with fibrinogen
129 values since direct fibrinogen measurement is not possible.(10)

130

131 **Objectives**

132 The Population, Index tests, and Target condition (PIT) framework(11) in this study is shown in
133 Table 1.(12)

134 Table 1: Population, Index tests, Target condition (PIT) framework

Population	Pregnant patients after 20 weeks gestation and postpartum patients.
Index tests	The following POCT devices are defined as index tests. 1. Dry haematology 2. Thromboelastography 3. Thromboelastometry
Target condition	Hypofibrinogenemia in patients with PPH

135 POCT, point-of-care testing; PPH, postpartum haemorrhage.

136 The purpose of this study is to perform a systematic review of the diagnostic accuracy of POCT
137 devices in diagnosing hypofibrinogenaemia in patients with PPH. The population, index test, and
138 target conditions are presented in Table 1. The reference standard for diagnosing
139 hypofibrinogenaemia will be based on fibrinogen levels measured using the conventional Clauss
140 method, and the cut-off value for diagnosing hypofibrinogenaemia will be determined based on the
141 values set in each individual study. Figure 1 shows the clinical flowchart of the included studies.

142

143 **Significance of this review**

144 As mentioned above, there have been numerous reports on the usefulness of POCT devices in
145 emergency medicine and cardiovascular surgery. However, there are few reports on their use in PPH.
146 Compared to non-pregnant women, pregnant women are characterised by circulatory dynamics and
147 blood coagulability. In pregnant women, the circulating blood volume is increased by up to 50%, all
148 coagulation factor activities except for factor 13 are increased, and the fibrinolytic system is
149 relatively suppressed.(12,13) Since fibrinogen requires the highest concentration of any coagulation
150 factor during haemostasis, high-volume transfusion in the setting of PPH is easily complicated by
151 dilutional coagulopathy.(14,15) In addition, PPH consumes large amounts of coagulation factors to
152 stop bleeding from the placental abruption site, which may result in consumptive coagulopathy.(16)
153 Since fibrinogen is the first to be consumed in these coagulation disorders, DIC progresses more

154 rapidly in PPH than in other haemorrhagic diseases. Therefore, given the unique aspects of
155 pregnancy, it is necessary to investigate the effectiveness of POCT devices separately in patients
156 with PPH.

157 If POCT devices demonstrate high diagnostic accuracy for detecting hypofibrinogenaemia in PPH,
158 they can be used to guide treatment strategies for the early identification of coagulation disorders
159 and appropriate transfusion therapy.

160

161 **METHODS AND ANALYSIS**

162 This systematic review and meta-analysis follows the Preferred Reporting Items for Systematic
163 Reviews and Meta-Analyses (PRISMA) statement and the PRISMA-Diagnostic Test Accuracy
164 (DTA) statement.(17,18) The study protocol was registered with University Hospital Medical
165 Information Network Clinical Trials (UMIN000048272) and PROSPERO (CRD42023394785).

166

167 **Eligibility criteria**

168 *Participants*

169 Pregnant women and postpartum women after 20 weeks gestation and patients with blood loss
170 >1000 ml will be included. To examine the effectiveness of POCT devices in investigating the
171 parameters of bleeding in pregnant women, studies that only include pregnant women with
172 congenital coagulopathy will be excluded.

173 *Setting*

174 Studies in which the initial treatment for PPH or follow-up after transfusion was administered with
175 POCT will be included. Pilot studies conducted on healthy pregnant women and postpartum mothers
176 will be excluded.

177 *index test*

178 Only studies using Dry haematology (e.g. CG02N®), Thromboelastography (e.g. TEG®), or
179 Thromboelastometry (e.g. ROTEM®) as an index test will be included.

180 *reference standard*

181 Only studies that use the Clauss method for fibrinogen measurement as the reference standard will
182 be included. There are three methods for measuring fibrinogen in blood: the Clauss method, the salt
183 precipitation method, and the immunoassay method. The Clauss method is the most widely used
184 internationally, and studies using salting-out and immunoassay methods are excluded.(19) A low
185 blood fibrinogen level in pregnant women is reported to be a risk for PPH at ≤ 200 mg/dl and a risk
186 for requiring massive blood transfusions at ≤ 130 – 155 mg/dl.(20–22) The definition of
187 hypofibrinogenaemia is inconsistent in the literature with fibrinogen ≤ 150 mg/dl and ≤ 200
188 mg/dl.(23) We plan to collect the literature regardless of the cut-off value of hypofibrinogenaemia

189 and integrate the results, and we will conduct a subgroup analysis according to the cut-off value if
190 there are a sufficient number of studies (i.e., \geq five studies) for each cut-off value.

191 *target condition*

192 This study will include only PPH patients diagnosed with hypofibrinogenemia.

193 *Types of studies*

194 Only studies involving humans will be included, and literature on animals will be excluded. Studies
195 will include randomised controlled trials (RCTs) and non-RCTs (non-randomised controlled trials,
196 split time-series analyses, before/after comparisons, cohort studies, and case-control studies).
197 Non-published studies (e.g. conference abstracts and clinical trial protocols) will also be included.

198

199 **Information sources and search strategy**

200 The literature will be searched using electronic databases such as MEDLINE, Embase, the Cochrane
201 Database, and Web of Science, and references to the corresponding literature will also be evaluated.

202 A literature search of these databases will be conducted on 15/06/2023.

203 The search formula for PubMed is shown below in Table 2.

204

Table 2: The search strategy for PubMed

Search Number	Query
1	"postpartum hemorrhage"[MeSH Terms] OR (postpartum[tiab] AND hemorrhage[tiab]) OR (postpartum[tiab] AND haemorrhage[tiab])
2	"point of care testing"[MeSH Terms] OR "Point-Of-Care"[tiab] OR (point*[tiab] AND care[tiab] AND test*[tiab])
3	dry[tiab] AND hematology[tiab]
4	"thrombelastography"[MeSH Terms] OR "Thromboelastometry"[tiab]
5	"blood coagulation tests"[MeSH Terms] OR (blood[tiab] AND coagulation[tiab] AND test*[tiab])
6	"viscoelasti*" [tiab] AND ("haemostat*" [tiab] OR "hemostatics"[MeSH Terms] OR "hemostasis"[MeSH Terms])
7	#2 OR #3 OR #4 OR #5 OR #6 OR #7
8	#1 AND #7

205

206 **Study selection**

207 *Data management and selection process*

208 The list of references obtained from the electronic databases will be scanned using literature
209 management software (EndNote®) to remove duplicate references. The titles and abstracts will be
210 screened by two independent reviewers (EN and YK) to assess the inclusion criteria. For references
211 determined to be eligible by at least one of the two reviewers in the primary screening, we will

212 proceed to the secondary screening process using the full text. Secondary screening using the full
213 text will be conducted for references that qualify in the primary screening and for those that cannot
214 be determined to be eligible based on the title and abstract. Disagreements regarding the eligibility
215 for the study will be resolved through discussion.

216

217 *Data collection process*

218 Two independent reviewers (EN and YK) will extract data from the eligible literature. If there are
219 discrepancies in data extraction between the two parties regarding the extraction of data, they will be
220 resolved through discussion.

221

222 *Data items*

223 Maternal age at delivery, weeks of delivery, primiparity, maternal body mass index, method of
224 delivery (vaginal or cesarean), cause of PPH (atonic bleeding, perineal laceration, retained or
225 adhered placenta, placental abruption, amniotic fluid embolism), total blood loss, total blood
226 transfusion requirements (Red Cell Concentrate, Fresh Frozen Plasma, Platelet Concentrate,
227 fibrinogen concentrate), maternal deaths, blood fibrinogen levels measured by the Clauss method at
228 the time of POCT device use, type of POCT device used, measurement results of POCT devices [(1)
229 dry-haematology: fibrinogen, (2) thromboelastography: R, K, MA, Ly30, A-10, FLEV, (3)
230 thromboelastometry: CT, CF, CFT, alpha, A10, MCF, LI30, LI60, ML], and the number of patients in
231 the true positive, false positive, true negative, and false positive will be collected as diagnostic
232 accuracy for hypofibrinogenemia.

233

234 **Outcomes and prioritization**

235 *Primary outcome*

236 The primary outcome is the diagnostic accuracy of the POCT device to determine
237 hypofibrinogenemia. Hypofibrinogenemia is diagnosed based on the fibrinogen values measured
238 using the Clauss method.

239 *Secondary outcomes*

240 The secondary outcome is the correlation coefficient between the fibrinogen value measured using
241 the Clauss method and the test values measured using POCT.

242

243 **Risk of bias in individual studies**

244 QUADAS-2 (24) will be used to assess the risk of bias for each study; QUADAS-2 is classified into
245 the following four domains: (1) participant selection, (2) index test, (3) reference standard, and (4)
246 flow and timing. For each domain, the risk of bias is classified as 'low', 'unclear', and 'high', and

247 concerns about applicability are also classified as 'low', 'unclear', and 'high'. Signalling questions are
248 also included to facilitate the evaluation of the risk of bias for each domain.

249

250 **Data synthesis and meta-analysis**

251 Firstly, we will present the predictive accuracy measures of individual studies based on the reported
252 counts of true positives, false positives, false negatives, and true negatives; sensitivities and
253 specificities will be calculated, accompanied by their corresponding 95% confidence intervals.
254 Coupled forest plots will be used to visualize sensitivities and specificities of POCT for diagnosing
255 hypofibrinogenaemia. In addition, scatter plots will be generated for pairs of sensitivities and
256 specificities to perform exploratory evaluations and assess heterogeneity.

257 Secondly, we will perform synthesis analyses using Reitsma's bivariate random-effects model to
258 account for possible heterogeneities across studies based on study-specific sensitivities and
259 specificities.(25) The results will be the summary estimates of sensitivities and specificities, along
260 with their heterogeneity variances (τ^2). Furthermore, we will generate summary receiver operating
261 characteristic (SROC) curves(26) based on bivariate random-effects model estimates and report the
262 areas under the curves (AUCs) as a summary measure of diagnostic accuracy.(27,28) For statistical
263 inference, we will employ standard restricted maximum likelihood estimation for Reitsma's
264 model(25) and use the bootstrap method to calculate 95% confidence intervals for the AUCs of the
265 SROC curves.(29) We will also perform a generalised Egger test for multivariate meta-analysis to
266 assess potential publication bias.(30) Statistical analyses will be performed using R software (R
267 Development Core Team, Vienna, Austria) and RStudio (RStudio, Boston, Massachusetts, USA).

268

269 **Confidence of cumulative evidence**

270 Once sufficient results have been obtained, the Grading of Recommendations, Assessment,
271 Development, and Evaluations (GRADE) will be used to evaluate the certainty of evidence.(31)

272

273 **Subgroup analyses**

274 If different thresholds for hypofibrinogenaemia are adopted among the eligible studies, subgroup
275 analyses will be considered according to the prespecified clinically relevant thresholds (≤ 150 mg/dl,
276 ≤ 200 mg/dl). In addition, to evaluate possible heterogeneity, subgroup analyses will be performed
277 based on the types of POCT devices used (dry haematology, thromboelastography, and
278 thromboelastometry).

279

280 **DISCUSSION**

281 Early detection of hypofibrinogenaemia in PPH and appropriate coagulation factor replacement are
282 crucial to improve the prognosis of PPH. However, no previous systematic review has reported the

283 usefulness of POCT devices in PPH. This systematic review focuses on the diagnostic accuracy of
284 POCT for hypofibrinogenaemia and may provide data for the effective use of POCT devices in PPH.
285 This study will focus on blood fibrinogen levels in patients with obstetric haemorrhage. Fibrinogen
286 level is the most important coagulation index in the blood of patients with PPH. Although many
287 coagulation factors are necessary for haemostasis, fibrinogen is required in the highest concentration
288 in the blood.(32) When massive haemorrhage occurs due to PPH, high-volume intravenous infusion
289 to maintain blood pressure can easily lead to dilutional coagulopathy.(33) Furthermore, there is a risk
290 of consumptive coagulopathy, in which a large amount of coagulation factors is consumed to stop
291 bleeding from the placental abruption surface. Moreover, fibrinogen is also the first to be
292 consumed.(34) Therefore, it is reasonable to assume that early recognition of hypofibrinogenemia
293 and appropriate blood transfusion therapy will improve the prognosis of PPH compared to other
294 massive haemorrhages.

295 In PPH, early identification of hypofibrinogenaemia and administering fibrinogen concentrate may
296 reduce the total amount of blood transfusion required and improve the prognosis.(23) Early
297 diagnosis of hypofibrinogenaemia using POCT devices and the development of transfusion protocols
298 may improve maternal outcomes in PPH and conserve medical resources, including transfusion
299 products.(35) This systematic review aims to determine the effectiveness of POCT in the diagnosis
300 of hypofibrinogenaemia in patients with PPH. If POCT devices are reliable for accurately diagnosing
301 hypofibrinogenaemia and determining the minimum transfusion volume needed to correct
302 coagulopathy, they could potentially increase maternal survival rates and reduce the burden on
303 medical resources.

304

305 **Limitations and implications**

306 This systematic review has several limitations. First, the heterogeneity among the studies may be an
307 issue. The threshold for diagnosing hypofibrinogenaemia, the definition of PPH, and the POCT
308 devices used may vary between studies and could be a potential source of heterogeneity. Second,
309 since most primary studies are observational, it is expected that many unpublished studies will exist.
310 Third, the applicability of the study results may be limited since this systematic review only pertains
311 to the use of POCT devices in pregnant patients with PPH. Fourth, the number of studies may be
312 limited since there is a wide variety of POCT devices used in PPH. If there are insufficient reports
313 for each device, the results of all POCT devices may be combined, making it difficult to determine
314 the most effective device since there will be no direct comparison between the devices.

315

316 **ETHICS AND DISSEMINATION**

317 This systematic review will finally be submitted for publication in a peer-reviewed journal. The data
318 used in this study do not include individual patient data, so there are no patient privacy concerns.

319 There are also no restrictions on the release of data. Any significant changes from this protocol will
320 be described in detail.

321

322 **Acknowledgements**

323 We would like to thank Editage (www.editage.com) for English-language editing.

324

325 **Author contributions**

326 Conceptualization: Ehisin Nakamura, Takahiro Mihara, Sayuri Shimizu

327 Methodology: Eishin Nakamura, Takahiro Mihara, Yuriko Kondo, Hisashi Noma

328 Supervision: Takahiro Mihara, Sayuri Shimizu, Hisashi Noma

329 Writing – Original Draft Preparation: Eishin Nakamura

330 Writing – Review & Editing: Eishin Nakamura, Takahiro Mihara, Yuriko Kondo, Hisashi Noma,
331 Sayuri Shimizu.

332

333 **Competing Interests**

334 None declared.

335

336 **Funding**

337 This research received no specific grant from any funding agency in the public, commercial or
338 not-for-profit sectors.

339

340 **Word count**

341 3876 words

342

343 **References:**

344 1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic
345 analysis. *Lancet Glob Health*. 2014;2:e323–33.

346 2. Era S, Matsunaga S, Matsumura H, et al. Usefulness of shock indicators for determining
347 the need for blood transfusion after massive obstetric hemorrhage. *J Obstet Gynaecol Res*
348 2015;41:39–43.

349 3. Collins PW, Cannings-John R, Bruynseels D, et al. Viscoelastometry guided fresh frozen
350 plasma infusion for postpartum haemorrhage: OBS2, an observational study. *Br J Anaesth*
351 2017;119:422–34.

352 4. Hayakawa M, Gando S, Ono Y, et al. Rapid evaluation of fibrinogen levels using the
353 CG02N whole blood coagulation analyzer. *Semin Thromb Hemost* 2015;41:267–71.

- 354 5. Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. *Semin*
355 *Thromb Hemost* 2017;43:386–96.
- 356 6. Da Luz LT, Nascimento B, Shankarakutty AK, et al. Effect of thromboelastography
357 (TEG®) and rotational thromboelastometry (ROTEM®) on diagnosis of coagulopathy, transfusion
358 guidance and mortality in trauma: descriptive systematic review. *Crit Care*. 2014;18:1–26.
- 359 7. Ogawa S, Tanaka KA, Nakajima Y, et al. Fibrinogen measurements in plasma and whole
360 blood: a performance evaluation study of the dry-hematology system. *Anesth Analg*.
361 2015;120:18–25.
- 362 8. Othman M, Kaur H. Thromboelastography (TEG). *Methods Mol Biol* 2017;1646:533–43.
- 363 9. Schöchl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major
364 trauma patients using thromboelastometry (ROTEM®)-guided administration of fibrinogen
365 concentrate and prothrombin complex concentrate. *Crit Care* 2010;14:1–11.
- 366 10. Lloyd-Donald P, Churilov L, Cheong B, et al. Assessing TEG6S reliability between
367 devices and across multiple time points: A prospective thromboelastography validation study. *Sci*
368 *Rep* 2020;10:7045.
- 369 11. Leeflang MM, Davenport C, Bossuyt PM. Chapter 6: Defining the review question. 2022.
- 370 12. Hill CC, Pickinpaugh J. Physiologic changes in pregnancy. *Surg Clin North Am*
371 2008;88:391–401.
- 372 13. Hui C, Lili M, Libin C, et al. Changes in coagulation and hemodynamics during
373 pregnancy: a prospective longitudinal study of 58 cases. *Arch Gynecol Obstet* 2012;285:1231–6.
- 374 14. Zentai C, Van Der Meijden PEJ, Braunschweig T, et al. Hemostatic therapy using
375 tranexamic acid and coagulation factor concentrates in a model of traumatic liver injury. *Anesth*
376 *Analg* 2016;123:38–48.
- 377 15. Levy JH, Szlam F, Tanaka KA, et al. Fibrinogen and hemostasis: a primary hemostatic
378 target for the management of acquired bleeding. *Anesth Analg*. 2012;114:261–74.
- 379 16. Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its
380 acute haematological management. *Blood Rev* 2009;23:167–76.
- 381 17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and
382 meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6:336–41.
- 383 18. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al.
384 Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy
385 Studies: The PRISMA-DTA Statement. *JAMA*. 2018 Jan 23;319(4):388–96.
- 386 19. Stang LJ, Mitchell LG. Fibrinogen. *Methods in Molecular Biology*. 2013;992:181–92.
- 387 20. Cortet M, Deneux-Tharoux C, Dupont C, Colin C, Rudigoz RC, Bouvier-Colle MH, et al.
388 Association between fibrinogen level and severity of postpartum haemorrhage: Secondary analysis
389 of a prospective trial. *Br J Anaesth*. 2012;108(6):984–9.

- 390 21. Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, et al. The decrease of
391 fibrinogen is an early predictor of the severity of postpartum hemorrhage. *Journal of Thrombosis and*
392 *Haemostasis*. 2007 Feb 1;5(2):266–73.
- 393 22. Wang L, Matsunaga S, Mikami Y, Takai Y, Terui K, Seki H. Pre-delivery fibrinogen
394 predicts adverse maternal or neonatal outcomes in patients with placental abruption. *Journal of*
395 *Obstetrics and Gynaecology Research*. 2016 Jul 1;42(7):796–802.
- 396 23. Matsunaga S, Takai Y, Seki H. Fibrinogen for the management of critical obstetric
397 hemorrhage. *J Obstet Gynaecol Res*. 2019 Jan 1;45(1):13–21.
- 398 24. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.
399 QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern*
400 *Med*. 2011 Oct 18;155(8):529–36.
- 401 25. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH.
402 Bivariate analysis of sensitivity and specificity produces informative summary measures in
403 diagnostic reviews. *J Clin Epidemiol*. 2005;58:982–90.
- 404 26. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of
405 diagnostic test accuracy evaluations. *Stat Med* 2001;20:2865–84.
- 406 27. Leeflang MMG, Deeks JJ, Gatsonis C, et al. Systematic reviews of diagnostic test
407 accuracy. *Ann Intern Med* 2008;149:889–97.
- 408 28. Macaskill P, Gatsonis C, Deeks J, et al. *Cochrane Handbook for Systematic Reviews of*
409 *Diagnostic Test Accuracy*.
- 410 29. Noma H, Matsushima Y, Ishii R. Confidence interval for the AUC of SROC curve and
411 some related methods using bootstrap for meta-analysis of diagnostic accuracy studies. *Commun*
412 *Stat Case Stud Data Anal Appl* 2020;7:344–58.
- 413 30. Hong C, Salanti G, Morton SC, et al. Testing small study effects in multivariate
414 meta-analysis. *Biometrics*. 2020;76:1240.
- 415 31. GRADE Working Group. Grading quality of evidence and strength of recommendations.
416 *BMJ*. 2004;328:1490–4.
- 417 32. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood
418 loss with plasma-poor red cell concentrates. *Anesth Analg* 1995;81:360–5.
- 419 33. Levy JH, Szlam F, Tanaka KA, et al. Fibrinogen and hemostasis: a primary hemostatic
420 target for the management of acquired bleeding. *Anesth Analg* 2012;114:261–74.
- 421 34. Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its
422 acute haematological management. *Blood Rev* 2009;23:167–76.
- 423 35. Snegovskikh D, Souza D, Walton Z, et al. Point-of-care viscoelastic testing improves the
424 outcome of pregnancies complicated by severe postpartum hemorrhage. *J Clin Anesth* 2018;44:50–6.
425

426 **Figure legend:**

427 Figure 1: clinical flowchart of postpartum haemorrhage (PPH) patients

428

429

